A Review Study on Operational Parameters and Biological Reactors Suitability for VOC Biodegradation in Drug and Pharmaceutical Industrial Wastewater
Abstract
The majority of the components that make up pharmaceutical industry wastewater are solvents. During the treatment of treating this kind of industrial waste water, there is a significant risk of the emission of volatile organic compounds. The toxicity caused by solvents has a negative impact on the efficiency of anaerobic systems, while the considerable aeration that occurs during the aerobic process helps to increase the removal of volatile organic compounds into the atmosphere. The majority of the earlier experiments focused on removing COD from wastewater from pharmaceutical companies. It is necessary to have an understanding of the variables that promote the system of volatile organic compounds (VOCs) in biological systems in order to investigate the many solutions available for lowering their emission. Throughout this paper, the ways that volatile organic compounds (VOC) can be controlled from biological reactors are emphasized. This study came to the conclusion that biological systems with high biomass retention, longer hydraulic retention times, and controlled air flow speeds up the breakdown of volatile organic compounds (VOC) in wastewater. This leads to less VOC being released from wastewater treatment units, which is a good thing.
How to cite this article: Chakraborty S. A Review Study on Operational Parameters and Biological Reactors Suitability for VOC Biodegradation in Drug and Pharmaceutical Industrial Wastewater. J Durg Dis Dev 2022; 6(1): 14-18.
References
Chen, W.H., Yang, W.B., Yuan, C.S., Yang, J.C. and Zhao, Q.L. (2013). Influences of aeration and biological treatment on the fates of aromatic VOCs in wastewater treatment processes. Aerosol and Air Quality Research, 13: 225-236.
Dawery, S. (2013). Methanol removal from methanol-water mixture using municipal activated sludge. Journal of Engineering Science and Technology, 8(5): 578-587.
EPA (2006) Toxic Release Inventory, U.S. Environmental Protection Agency, http:// www.epa.gov/tri/tridata/tri05/index.htm. Last accessed, 10, January, 2010.
Hsi, C.W. (2009). Using a biological aerated filter to treat mixed water-borne volatile organic compounds and assessing its emissions. Journal of Environmental Sciences, 21: 1497–1502.
Hsieh, C. C. (2000). Removal mechanisms of VOCs in an activated sludge process. Journal of hazardous materials, 79(1):173-187.
Masse, A., Sperandio, M., Cabassud, C. (2006). Comparison of sludge characteristics and performance of a submerged membrane bioreactor and an activated sludge process at high solids retention time. Water Research, 40:2405-2415.
Ming, W.Y., Min, Y., Yu, Z., Chun, G.M. and Jing, Z. (2004). Biological removal of methanol from process condensate for the purpose of reclamation. Journal of Environmental Science 16(3): 384-386.
Moura, S.C., Jorge, R.F., Duque, A., Boaventura, R.A.R . and Castro, P.M.L. (2007). Aerobic biological treatment of wastewaters containing dichloromethane. Journal of Chemical Technology and Biotechnology, 82: 864–869.
Oktem, Y. A., Ince, O., Sallis, P., Donnelly, T and Ince, B. K. (2007). Anaerobic treatment of a chemical synthesis-based pharmaceutical wastewater in a hybrid upflow anaerobic sludge blanket reactor. Bioresource Technology, 99: 1089–1096.
Oz, N.A., Ince, O and Ince, B.K. (2004).Effect of wastewater composition on methanogenic activity in an anaerobic reactor. Journal of Environmental Science and Health, Part A: Toxic/Hazardous Substances and Environmental Engineering, 39 (11-12) : 2941-2953.
Ozdemir, C., Sen, N., Dursun, S. and Kalipchi, E. (2010). Removal of dichloromethane in up-flow anaerobic sludge bed reactors and methane production. Asian Journal of Chemistry, 22(8): 6423-6436.
Priya, V. S., and Philip. L., (2015a). Treatment of volatile organic compounds in pharmaceutical wastewater using submerged aerated biological filter. Chemical Engineering Journal, 266: 309-319.
Priya, V. S., and Philip. L., (2015b.). Membrane bioreactor for the treatment of voc laden pharmaceutical wastewater: Effect of biological treatment systems on membrane performance. Journal of Water Process Engineering, 7:61-73.
Quesnel, D., Nakhla, G. (2006). Removal kinetics of acetone and MIBK from a complex industrial wastewater by an acclimatized activated sludge. Journal of Hazardous Material B, 132: 253-260.
Raghuvanshi, S., Gupta, S. and Babu, B. V. (2013). Growth Kinetics of Acclimated Mixed Culture for Degradation of Isopropyl Alcohol (IPA). Journal of Biotechnology & Biomaterials.
Raj, D.S.S., and Anjaneyulu, Y. (2005). Evaluation of biokinetic parameters for pharmaceutical wastewaters using aerobic oxidation integrated with chemical treatment. Process Biochemistry, 40:165-175.
Saleem, M. (2007). Pharmaceutical wastewater treatment: a physicochemical study. Journal of Research (Science), 18(2):125-134.
Saravanane, R., Murthy, D.V.S. and Krishnaiah, K. (2001). Treatment of anti-osmotic drug based pharmaceutical effluent in an upflow anaerobic fluidized bed system. Waste Management, 22: 563-568.
Sirtori, C., Zapata, A., Oller, I., Gernjak, W., Agüera, A.and Malato, S. (2009). Decontamination industrial pharmaceutical wastewater by combining solar photo-Fenton and biological treatment. Water Research, 43(3), 661-668.
Tekin, H., Selale S.O.B., Ataberk, A. and Balta, T.H. (2006). Use of Fenton oxidation to improve the biodegradability of a pharmaceutical wastewater. Journal of Hazardous Materials B, 136; 258-265.
Wang, Z., Xiu, G., Qiao, T., Zhao, K. and Zhang, D. (2013). Coupling ozone and hollow fibers membrane bioreactor for enhanced treatment of gaseous xylene mixture. Bioresource technology, 130: 52-58.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Journal of Drug Discovery and Development ( ISSN:2581-6861)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
We, the undersigned, give an undertaking to the following effect with regard to our article entitled
“_______________________________________________________________________________________________________________________________________________________________________________
________________________________________________________________________________” submitted for publication in (Journal title)________________________________________________ _______________________________________________________Vol.________, Year _________:-
1. The article mentioned above has not been published or submitted to or accepted for publication in any form, in any other journal.
2. We also vouchsafe that the authorship of this article will not be contested by anyone whose name(s) is/are not listed by us here.
3. I/We declare that I/We contributed significantly towards the research study i.e., (a) conception, design and/or analysis and interpretation of data and to (b) drafting the article or revising it critically for important intellectual content and on (c) final approval of the version to be published.
4. I/We hereby acknowledge ADRs conflict of interest policy requirement to scrupulously avoid direct and indirect conflicts of interest and, accordingly, hereby agree to promptly inform the editor or editor's designee of any business, commercial, or other proprietary support, relationships, or interests that I/We may have which relate directly or indirectly to the subject of the work.
5. I/We also agree to the authorship of the article in the following sequence:-
Authors' Names (in sequence) Signature of Authors
1. _____________________________________ _____________________________________
2. _____________________________________ _____________________________________
3. _____________________________________ _____________________________________
4. _____________________________________ _____________________________________
5. _____________________________________ _____________________________________
6. _____________________________________ _____________________________________
7. _____________________________________ _____________________________________
8. _____________________________________ _____________________________________
Important
(I). All the authors are required to sign independently in this form in the sequence given above. In case an author has left the institution/ country and whose whereabouts are not known, the senior author may sign on his/ her behalf taking the responsibility.
(ii). No addition/ deletion/ or any change in the sequence of the authorship will be permissible at a later stage, without valid reasons and permission of the Editor.
(iii). If the authorship is contested at any stage, the article will be either returned or will not be
processed for publication till the issue is solved.
